Navigation Links
Long-term hormone replacement therapy increases breast cancer risk
Date:5/28/2008

Are you taking or did you take hormones? If yes, which hormone medication and for how long? When did you stop taking hormone replacement medication? 3,464 breast cancer patients and 6,657 healthy women between the ages of 50 and 74 years participated in a large survey and elicited detailed information about hormone replacement medications they are taking or used to take for relief of menopausal symptoms. The survey was prompted by the MARIE case-control study carried out by the German Cancer Research Center (DKFZ) and the University Hospitals in Hamburg-Eppendorf, Germany. The goal of this 6-year study, which was financed by the German Cancer Aid (Deutsche Krebshilfe), was to determine the effect of hormones both on their own and in association with other factors on breast cancer risk.

Women who have taken menopausal hormone therapy before have a 37 percent higher risk of breast cancer than women who have never taken hormone replacement therapy (HRT). During the actual time of HRT use the risk is even elevated by 73 percent. Within five years after cessation of therapy the risk of breast cancer in former HRT users falls back to the level of women who never used HRT. These results of the MARIE study confirm findings of two U.S. and U.K. studies (Womens Health Initiative Study and Million Women Study) that caused a stir in 2002 and 2003, says Professor Dr. Wilhelm Braendle of Hamburg-Eppendorf University Hospitals, who headed the study.

It has often been argued that the results of the U.S. study could not be applied to Germany where prescription practices are completely different. Therefore, we captured the various hormone preparations, especially the various progestins, very precisely. We have obtained similar results as the U.S. researchers, Professor Dr. Jenny Chang-Claude of DKFZ summarizes. With our new data, we provide physicians in Germany with solid information that will help them to advise their patients about the benefits and risks of hormone replacement therapy.

The MARIE study also confirms that different hormone preparations have different effects: Compared to the risk of women who have never used HRT, a combined therapy of estrogen and progestin doubles the risk of breast cancer, while use of estrogen alone (estrogen replacement therapy) raises the risk by only 15 percent. However, in both cases the risk increases only if hormones are taken for more than five years.

Hormone replacement therapy also appears to have a different influence on different types of breast cancer, Braendle explains. The risk of developing one of the less common lobular or tubular breast cancers increases twice as much under HRT as the risk of the common type of ductal carcinoma, which constitutes 40 to 75 percent of all malignant tumors of the breast.


'/>"/>

Contact: Dr. Sibylle Kohlstdt
s.kohlstaedt@dkfz.de
Helmholtz Association of German Research Centres
Source:Eurekalert

Related medicine news :

1. Study concludes no racial disparities in long-term outcomes in recipients of liver transplants
2. Long-term cognitive decline in bypass patients not due to surgery
3. Dont Wait for the Election to Plan Your Long-Term Healthcare, Insurance Leader Advises
4. New Data Shows Continued Growth of Long-Term Disability Claims and Decline in Social Security Disability Insurance Applications Approval Rate
5. APIC Recommendations on Infection Prevention in Long-Term Care Facilities
6. Ohio Health Care Association Elects North Canton Long-Term Care Provider as President
7. After divorce, stable families help minimize long-term harm to children
8. Ohio Health Care Association Hosts Midwests Largest Long-Term Care Convention in Columbus
9. SAPPHIRE trial shows long-term benefit of carotid stenting as alternative to surgery
10. 2004 long-term care act raised costs and worsened care, study shows
11. Childhood Leukemia Survivors Struggle With Long-Term Comorbidities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... The Data ... today that it was acquired by Advantage Solutions. The Data Council’s IX-ONE ... members include the industry’s leading suppliers, brokers, distributors and retailers. The Data Council ...
(Date:8/16/2017)... Va. (PRWEB) , ... August 16, 2017 , ... ... America (BIAA) is collaborating with a New England student to educate the public ... to acclaim in 2016 for launching the first-ever National Concussion Awareness Day. , ...
(Date:8/16/2017)... New York (PRWEB) , ... August 16, 2017 , ... ... could minimize its appearance with diet and exercise. In fact, cellulite can't always be ... a safer and more effective treatment available to select physicians nationwide. Dr. Kenneth Rothaus ...
(Date:8/16/2017)... ... 16, 2017 , ... Modern Consulting Insurance & Financial Services ... once again with Boys & Girls Clubs of Greater Kansas City, the agency ... own American Idol. With all proceeds benefitting local worthy causes, donations may be ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... received a three-year grant totaling $975,000, renewing its funding from the Health Resources ... Services. , This funding marks, the fourth time the HRSA administration has renewed ...
Breaking Medicine News(10 mins):
(Date:8/1/2017)... Aug. 1, 2017   CerSci Therapeutics , a ... Texas , has received notice from the National ... of Health (NIH) that it has been awarded a ... over $650,000 in 2017 with an additional $1,000,000 to ... New Drug application of their lead non-opioid drug candidate ...
(Date:7/28/2017)... --EnvoyHealth, a Diplomat company, has partnered with Compliance Meds ... a technology designed to improve patient medication adherence. ... solutions and services that help track and improve patients, ... LITE offers medication monitoring and control for patients and ... Records date and time of bottle ...
(Date:7/26/2017)... BEACH, Fla. , July 26, 2017 ... of enrollment of our clinical trial evaluating Altemia TM ... Cell Anemia (SCA) and Sickle Cell Disease (SCD). The ... to evaluate the efficacy and safety of Altemia TM ... trial is conducted under US IND 125274. ...
Breaking Medicine Technology: